Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ribometrix, Inc.
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.
Private Company Edition: Jeito says its new first fund is Europe’s largest life science-focused fund. Illumina will use its venture capital to support tools, diagnostics, therapeutics and more. Also, IASO closed a $108m series C round and Amolyt raised $80m in series C financing.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
Deal snapshot: Roche’s third partnership around small molecule, RNA-targeted therapies taps Ribometrix’s three-dimensional structural analysis of RNA to find pockets amenable to small molecule drugs.
- Antisense, Oligonucleotides